IRVINE, Calif.--(BUSINESS WIRE)--Nov. 15, 2018--
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical
company focused on developing products for patients with disorders of
the ear, nose, and throat (ENT), today announced that management will
participate in the 30th Annual Piper Jaffray Health Care Conference to
be held November 27-29, 2018 at the Lotte New York Palace. Gregory J.
Flesher, CEO of Novus Therapeutics, is scheduled to present a company
overview at 12:50 pm EST on Wednesday, November 28, 2018.
About Novus Therapeutics
Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company
focused on developing products for patients with disorders of the ear,
nose, and throat (“ENT”). Novus has two technologies, each that has the
potential to be developed for multiple ENT indications. Novus’ lead
product candidate (OP-02) is a surfactant-based, combination drug
product being developed as a potential first-in-class treatment option
for patients at risk for, or with, otitis media (“OM” or middle ear
inflammation with or without infection). Globally, OM affects more than
700 million adults and children every year, with over half of cases
occurring in children under five years of age. OM is one of the most
common disorders seen in pediatric practice, and in the United States is
a leading cause of health care visits and the most frequent reason
children are prescribed antibiotics or undergo surgery. Novus also has a
foam-based drug delivery technology (OP-01), which may be developed in
the future to deliver drugs into the ear, nasal, and sinus cavities. For
more information please visit novustherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005013/en/
Source: Novus Therapeutics, Inc.
LifeSci Advisors, LLC
Timothy McCarthy, (212) 915-2564